Market Access
Strengthen Your Reimbursement Pathway with a Strong Market Access Strategy
Successful commercialization requires more than clinical efficacy—it demands a strong market access strategy that demonstrates value to payers, HTA bodies, and healthcare systems. Thelansis helps biopharma companies optimize pricing, reimbursement, evidence generation, and market access by integrating payer insights, health economics, competitive intelligence, and regulatory expertise. We assess payer expectations, pricing, cost-effectiveness, clinical differentiation, and healthcare priorities to develop evidence-based strategies that accelerate reimbursement, market entry, and long-term commercial success.
Evidence-Based Market Access
Pricing & Reimbursement Readiness
Commercial Strategy Alignment
Why Market Access Matters
Regulatory approval no longer guarantees commercial success. Healthcare systems worldwide face increasing budget constraints, making reimbursement decisions more selective and evidence-driven than ever before.
Payers, HTA agencies, and policymakers evaluate therapies based not only on clinical outcomes but also on comparative effectiveness, economic value, patient benefits, and overall impact on healthcare resources.
Without an effective market access strategy, organizations may encounter:
- Delayed reimbursement approvals
- Restricted patient access
- Unfavorable HTA outcomes
- Lower return on investment
- Increased pressure during payer negotiations
By integrating market access planning early in the development process, companies can proactively address evidence gaps, strengthen their value propositions, and improve launch readiness across multiple markets.
A robust market access strategy aligns clinical development with payer expectations, ensuring that products generate meaningful value for patients while meeting the economic requirements of healthcare systems.
What We Do
Thelansis provides comprehensive market access consulting services across the product lifecycle. Our capabilities include:
Early Payer Value Assessment (EPVA)
Pricing Strategy Development
Health Technology Assessment Support
Access Barrier Identification
Value Proposition and Value Story Development
Launch Sequencing
Our Market Access Framework
At Thelansis, we combine clinical expertise, health economics, payer intelligence, and competitive analysis to develop customized market access strategies that support successful commercialization. Our multidisciplinary framework evaluates products from multiple stakeholder perspectives to ensure pricing and reimbursement strategies are grounded in evidence and aligned with market realities.
- Early Payer Value Assessment (EPVA)
- Pricing and Reimbursement Landscape Analysis
- Health Technology Assessment (HTA) Readiness
- Value Proposition Development
- Evidence Generation Planning
- Launch Sequencing and Market Prioritization
We Provide Answers to Critical Questions
Our market access analyses help organizations answer strategic questions such as:
What will payers consider meaningful value in this indication?
What evidence gaps may limit pricing power or access?
How should we position our product against competitors to secure reimbursement?
What market access risks require mitigation before commercialization?
How will HTA agencies evaluate our evidence package?
Which countries should be prioritized for launch?
Key Deliverables
Our market access engagements generate practical deliverables that support informed decision-making and successful commercialization. Typical outputs include:
Early payer value assessment (EPVA)
Pricing and reimbursement landscape reports
Market access strategy documents
HTA readiness assessments
Value story development
Access barrier analyses
Evidence generation roadmaps
Launch sequencing recommendations
Country prioritization matrices
Executive presentations
Benefits of Partnering with Thelansis
Organizations partnering with Thelansis gain a strategic advantage by integrating payer perspectives early into product development and commercialization planning. Our clients benefit from:
Faster reimbursement timelines
Stronger payer negotiations
Improved pricing strategies
Enhanced HTA readiness
Accelerated patient access
Reduced evidence gaps
Increased likelihood of premium market positioning
Better alignment between clinical and commercial objectives
Sustainable long-term commercial success
Unlock Global Market Access & Maximize Reimbursement Success
Our Market Access expertise goes beyond standard analysis—translating payer insights, HTA expectations, and health economics into actionable pricing and launch strategies for your portfolio.